Display options
Cite
Dashti-Khavidaki S, Shojaie L, Hosni A, et al. Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient. Nephrourol Mon. 2015;7(3):e27073doi: 10.5812/numonthly.7(3)2015.27073.
Dashti-Khavidaki, S., Shojaie, L., Hosni, A., Khatami, M. R., & Jafari, A. (2015). Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient. Nephro-urology monthly, 7(3), e27073. https://doi.org/10.5812/numonthly.7(3)2015.27073
Dashti-Khavidaki, Simin, et al. "Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient." Nephro-urology monthly vol. 7,3 (2015): e27073. doi: https://doi.org/10.5812/numonthly.7(3)2015.27073
Dashti-Khavidaki S, Shojaie L, Hosni A, Khatami MR, Jafari A. Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient. Nephrourol Mon. 2015 May 23;7(3):e27073. doi: 10.5812/numonthly.7(3)2015.27073. eCollection 2015 May. PMID: 26034746; PMCID: PMC4450162.
Copy Download .nbib Format: NLM
Share it on

Nephrourol Mon. 2015 May 23;7(3):e27073. doi: 10.5812/numonthly.7(3)2015.27073. eCollection 2015 May.

Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient.

Nephro-urology monthly

Simin Dashti-Khavidaki, Lida Shojaie, Amin Hosni, Mohammad Reza Khatami, Atefeh Jafari

Affiliations

  1. Nephrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  2. Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 26034746 PMCID: PMC4450162 DOI: 10.5812/numonthly.7(3)2015.27073

Abstract

BACKGROUND: Antibody mediated rejection (AMR) and thrombotic microangiopathy (TMA) after kidney transplantation are difficult to differentiate most of the times and both play important roles in kidney allograft loss. Common treatment strategies of these two conditions include plasmapheresis, intravenous immunoglobulin (IVIG) and rituximab.

OBJECTIVES: This study was designed to assess the efficacy of routine treatment of AMR/TMA in Iranian kidney transplant recipients, which comprises of plasmapheresis and IVIG.

PATIENTS AND METHODS: This one-year cross-sectional study was performed in the Kidney Transplantation Ward of Imam-Khomeini Hospital Complex, Tehran, Iran. All kidney transplant recipients who were administered plasmapheresis and IVIG to treat definite or suggested AMR or TMA were assessed clinically and also evaluated on laboratory data.

RESULTS: During 2014, we encountered five patients with suspicious AMR or TMA at our kidney transplant center. Renal biopsy was performed for two of them, suggesting AMR for one patient and TMA for another patient. All patients were treated with plasmapheresis plus IVIG. In this center, as a routine practice, the cumulative dose of 2 g/kg of IVIG was divided to 300 - 400 mg/kg after each plasmapheresis. Only one out of the five patients showed response, albeit not completely.

CONCLUSIONS: Due to daily plasmapheresis within the first several days after AMR or TMA, administering high amounts of the cumulative dose of IVIG after plasmapheresis may result in high amounts of IVIG withdrawal by plasmapheresis and response failure. Our suggestion is to reduce the IVIG dose after each plasmapheresis to 100 mg/kg (i.e. replacement dose) to reach a cumulative dose of 2 g/Kg. If plasmapheresis treatment is initiated sooner than the completion of the IVIG cumulative dose of 2 g/kg, the remaining dose can be administered during one injection.

Keywords: Graft Rejection; Immunoglobulins, Intravenous; Kidney Transplantation; Plasmapheresis; Thrombotic Microangiopathy

References

  1. Immunol Res. 2000;22(2-3):137-46 - PubMed
  2. N Engl J Med. 2001 Sep 6;345(10):747-55 - PubMed
  3. Transplantation. 2004 Sep 15;78(5):772-4 - PubMed
  4. J Am Soc Nephrol. 2007 Apr;18(4):1046-56 - PubMed
  5. J Clin Pathol. 2010 Jan;63(1):26-37 - PubMed
  6. Blood. 2010 Feb 25;115(8):1500-11; quiz 1662 - PubMed
  7. Am J Transplant. 2010 Mar;10(3):582-9 - PubMed
  8. Am J Transplant. 2010 Jul;10(7):1517-23 - PubMed
  9. Crit Care Med. 2012 Jan;40(1):104-11 - PubMed
  10. Semin Immunol. 2012 Apr;24(2):136-42 - PubMed
  11. Semin Immunol. 2011 Aug;23(4):224-34 - PubMed
  12. World J Urol. 2013 Aug;31(4):893-900 - PubMed
  13. Nat Rev Nephrol. 2012 Jan 31;8(3):131 - PubMed
  14. Semin Dial. 2012 Mar-Apr;25(2):214-9 - PubMed
  15. Transfusion. 2013 Mar;53(3):661-7 - PubMed
  16. Transplantation. 2012 Oct 27;94(8):775-83 - PubMed
  17. Lancet. 2013 Jan 26;381(9863):313-9 - PubMed
  18. J Thromb Haemost. 2013 Mar;11(3):481-90 - PubMed
  19. Am J Transplant. 2014 Feb;14(2):255-71 - PubMed
  20. Pharmacotherapy. 2014 Jul;34(7):733-44 - PubMed
  21. N Engl J Med. 2014 Aug 14;371(7):654-66 - PubMed
  22. Curr Transplant Rep. 2014 Jun;1(2):78-85 - PubMed

Publication Types